BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Medivation, Inc. 

525 Market Street
36th Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at http://www.medivation.com/

 Key Statistics


Email: info@medivation.com
Ownership: Public

Web Site: Medivation, Inc.
Employees: 18
Symbol: MDVN
 





Collaborations

Pfizer 





 Company News
Biotech Predictions for Large Cap Firms Include Medivation, Inc. (MDVN), Gilead Sciences, Inc. (GILD) 12/18/2014 12:15:08 PM
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conference 12/18/2014 9:55:25 AM
Medivation, Inc. (MDVN) And Astellas Pharma Inc. (ALPMY) Phase 3 PREVAIL Trial Named Clinical Advance Of The Year By SCRIP 12/12/2014 11:04:46 AM
Analysts Not Sold On Medivation, Inc. (MDVN)’s Xtandi as Breast Cancer Drug 12/10/2014 2:33:00 PM
Joseph Lobacki To Become Medivation, Inc. (MDVN)'s Chief Commercial Officer 11/26/2014 8:12:26 AM
Medivation, Inc. (MDVN) CEO David Hung Named National EY Entrepreneur Of The Year 2014 Overall Award Winner 11/19/2014 5:22:47 PM
Dr. David Hung, Founder, President And CEO Of Medivation, Inc. (MDVN), Named EY Entrepreneur Of The Year™ 2014 National Overall Award Winner 11/17/2014 12:06:13 PM
Medivation, Inc. (MDVN) Reports Third Quarter Financial Results And Provides Corporate Update 11/7/2014 12:17:12 PM
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conference 11/6/2014 1:55:09 PM
Medivation, Inc. (MDVN) And Astellas Pharma US Announce Phase 3 Study Of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy 10/31/2014 12:45:31 PM
12345678910...